

1 **Assessing non-white ethnic participation in type 2 diabetes mellitus randomized**  
2 **clinical trials: A Meta-Analysis**

---

3  
4 Rabeeyah Ahmed BArtsSc<sup>1</sup>, Russell J. de Souza ScD RD<sup>2</sup>, Vincent Li BSc<sup>3</sup>, Sonia. S. Anand MD  
5 PhD FRCP(C)<sup>2,3</sup>

6  
7 **Non-white ethnic participation in T2DM Trials:**

8  
9 <sup>1</sup> Arts and Science Program, McMaster University, Hamilton, Ontario, Canada

10 <sup>2</sup> Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton,  
11 Ontario, Canada

12 <sup>3</sup> Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario,  
13 Canada

14  
15  
16  
17

18 **Correspondence to:**

19 Dr. Sonia Anand,  
20 Chanchlani Research Centre  
21 McMaster University, Hamilton,  
22 ON L8S 4L8, Canada

23  
24  
25  
26

27 **Word Count: 3253**

28

29 **Number of tables: 2**

30

31 **Number of figures: 3**

32

33

34

35

36

37

38 **Key Points**

39 **Question:** What is the representation of non-white participants in type 2 diabetes randomized  
40 clinical trials relative to their disease burden?

41 **Findings:** In this meta-analysis, non-white participants are underrepresented in both  
42 government- and industry- funded type 2 diabetes randomized trials, compared to white  
43 participants. The greatest disparity in ethnic diversity in randomized trials was observed for those  
44 funded by industry.

45 **Meaning:** Deliberate strategies to improve recruitment and enrolment of diverse participants  
46 proportional to the type 2 diabetes disease burden into industry and government-funded  
47 randomized controlled trials are needed to enhance the generalizability of research findings.

49 **Abstract**

50 **Importance:** The prevalence of type 2 diabetes mellitus (T2DM) is increasing globally, and the  
51 greatest burden is borne by non-white ethnic groups. Randomized clinical trials (RCTs) provide  
52 evidence regarding the optimal medical therapy for the treatment of T2DM patients and inform  
53 national and international guidelines. However, there are concerns that the enrollment of  
54 ethnically diverse people into these trials is limited, which has resulted in a lack of ethnic  
55 diversity in RCTs of T2DM. Furthermore, the extent of underrepresentation may differ according  
56 to whether a trial is government-funded or industry-funded.

57

58 **Objective:** To systematically review and meta-analyze the proportion of non-white and white  
59 participants relative to their disease burden of T2DM included in large, influential government-  
60 and industry-funded RCTs of T2DM pharmacotherapies.

61

62 **Data Sources:** The PubMed electronic database was searched from January 2000 through  
63 January 2021.

64

65 **Study Selection:** Reports of RCTs of T2DM medications with a total sample size of at least 100  
66 participants published in the year 2000 onwards, in high impact general medical journals (i.e.,  
67 impact factor >10), were included.

68

69 **Data Extraction and Synthesis:** Data including the number of participants, proportion of  
70 participants by ethnicity, and funding sources, were extracted from trial reports.

71

72 **Main Outcomes and Measures:** The main outcome was the participation-to-prevalence ratio  
73 (PPR), which was calculated for each trial by dividing the percentage of white and non-white  
74 participants in the trial by the percentage of white and non-white participants with T2DM for the  
75 countries or regions of recruitment represented in each trial. A random-effects meta-analysis was  
76 used to generate the pooled PPR and 95% confidence intervals (CI) across study types. A PPR  
77  $<0.80$  indicates underrepresentation and  $>1.20$  indicates overrepresentation.

78

79 **Results:** A total of 82 trials were included involving 296,964 participants: 14 were government-  
80 funded trials, and 68 were industry-funded trials. For government trials, the PPR for white  
81 participants was 1.11 (95% CI; 1.00-1.23) and for non-white participants was 0.73 (95% CI:0.62-  
82 0.86). Among industry trials, the PPR for white participants was 2.19 (95%CI: 1.91-2.50), and  
83 the PPR for non-white participants was 0.33 (95%CI: 0.29-0.38). Heterogeneity was high across  
84 all PPRs.

85

86 **Conclusions and Relevance:** Non-white participants are underrepresented in both government-  
87 and industry- funded T2DM trials, compared to white participants. The greatest disparity in  
88 ethnic diversity in RCTs is observed for industry-funded trials.

## 89 **Introduction**

90 The burden of type 2 diabetes (T2DM) is disproportionately higher in non-white ethnic groups  
91 compared to white individuals.<sup>1</sup> However, individuals from non-white ethnic groups are  
92 generally underrepresented in clinical trials.<sup>1</sup> Randomized clinical trials (RCTs) are designed to  
93 produce the most reliable evidence on the efficacy and safety of various interventions.<sup>2</sup> As such,  
94 they inform treatment recommendations and prevention strategies for T2DM.

95 Underrepresentation of non-white individuals in RCTs can limit the generalizability and uptake  
96 of the trial findings among the groups with the highest disease burden.<sup>3</sup>

97

98 In some countries like the United States, the National Institutes of Health (NIH) provides  
99 guidelines for the inclusion of minority groups in NIH-funded clinical research,<sup>4</sup> a measure taken  
100 to improve the generalizability of research findings. Industry-funded trials do not have the same  
101 requirements as the NIH, nor do many other government-established funding agencies.<sup>5-8</sup> For  
102 example, Canada and Australia do not have guidelines for the recruitment of diverse populations  
103 into clinical trials. The “Guidance for Industry: Standards for Clinical Trials in Type 2 Diabetes  
104 in Canada” (2007) document does not mention the terms ‘race’ or ‘ethnicity,’ nor does it provide  
105 guidelines on participant recruitment.<sup>7</sup> Similarly, the Government of Australia’s guidelines for  
106 clinical trials do not include any regulations pertaining to ethnic recruitment.<sup>8</sup> In the United  
107 Kingdom (UK), there is also no requirement to record and report ethnicity in research studies.<sup>5</sup>

108

109 The NIH requirements are guided by the Public Health Service Act sec. 492B, 42 U.S.C. sec.  
110 289a-2 and are designed to enhance the inclusion of minority groups in NIH-funded research.<sup>4</sup>

111 Efforts to increase representation of minority groups in RCTs have been made internationally as

112 well. For example, some research institutions in the UK are taking measures to address the lack  
113 of ethnic participant recruitment guidelines for clinical trials. In 2018, the UK's National  
114 Institute for Health Research (NIHR) launched the INCLUDE project, which was designed to  
115 improve the diversity of research participants in clinical studies.<sup>5</sup> The NIHR also released new  
116 guidelines in 2020 in response to the COVID-19 pandemic. While these guidelines are intended  
117 to promote improvements in research practices related to COVID, the guidelines may also help  
118 improve the inclusion of diverse groups in other research areas.<sup>5</sup>

119  
120 We conducted a systematic review of RCTs testing at least one T2DM pharmacotherapy from  
121 January 2000 to January 2021 and investigated: i) the non-white ethnic participation relative to  
122 the disease burden of T2DM in large RCTs in which T2DM therapies were evaluated, and ii) the  
123 differences in non-white ethnic participation comparing industry and government-funded trials.

124

## 125 **Methods**

126 The systematic review was developed in accordance with the Preferred Reporting Items for  
127 Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines.

128

## 129 **Data Sources and Searches**

130 Guided by a clinical expert, a broad search strategy using medical subject heading (MeSH) terms  
131 and keywords related to T2DM randomized trials with relevant search terms (eTable 1 in the  
132 Supplement). Initially, the search was limited to trials published in “top-tier journals”, defined as  
133 an impact factor  $\geq 30$ , which included the New England Journal of Medicine, The Lancet,  
134 Journal of the American Medical Association, and British Medical Journal. This criterion was

135 kept for industry trials; however, it was expanded to include publications from three journals  
136 (Circulation, Diabetes Care, and Annals of Internal Medicine) with an impact factor  $\geq 10$  for  
137 government trials because few government-funded trials were published in journals with an  
138 impact factor  $\geq 30$ . The search was also initially limited to trials that recruited from at least two  
139 countries. This criterion was kept for industry trials; however, it was removed for government  
140 trials because government-funded trials are often conducted solely within the country that funded  
141 the research. A complete list of study selection criteria can be found in eTable 2 in the  
142 Supplement. Two reviewers independently searched the PubMed database from January 1, 2000  
143 to January 1, 2021 to identify relevant studies. PubMed was used because top journals are all  
144 indexed in the database, which eliminated the need for multiple database searching. After  
145 removing duplicates, the records were reviewed independently by one reviewer at the title and  
146 abstract level, followed by full-text screening by two reviewers in duplicate based on  
147 predetermined study selection criteria. Discrepancies were resolved by discussion with the senior  
148 author (SSA). Covidence (<https://www.covidence.org/>) was used for data management.

149

### 150 **Data Extraction**

151 Three reviewers independently abstracted the following information from published studies: title,  
152 year of publication, journal, funding source, pharmacotherapy intervention, total number of  
153 participants, number of white and non-white participants, number of female participants, and  
154 country or region of greatest participant recruitment. Discrepancies were cross-checked, and  
155 where necessary, were resolved by discussion with the senior author (SSA). The resource  
156 ClinicalTrials.gov and other publicly available web resources, were consulted to fill in any  
157 missing information that was not in the main articles or supplementary materials.

158

159 **Outcome Measures**

160 There were two outcomes of interest for this systematic review: the proportion of white  
 161 participants in government and industry-funded trials relative to the T2DM disease burden in the  
 162 population, and the proportion of non-white participants in government and industry-funded  
 163 trials relative to the T2DM disease burden in the population.

164

165 **Statistical Analysis**

166 The participation-to-prevalence ratio (PPR) metric was used to estimate the representation of  
 167 white participants, and the representation of non-white ethnic participants compared to their  
 168 respective disease burden, separately in industry and government-funded trials. The PPRs for  
 169 white participants and non-white participants in each trial was calculated using the respective  
 170 formulas below.

171 *PPR*

$$172 = \frac{\textit{Percentage of white participants in the trial (\%)}}{\textit{Percentage of white people among the diseased population (\%)}}$$

173

174

176 *PPR*

$$177 = \frac{\textit{Percentage of non – white participants in the trial (\%)}}{\textit{Percentage of non – white people among the diseased population (\%)}}$$

175

178 A PPR of 1 suggests that the specific ethnic group makes up the same proportion of participants  
179 in the trial as of the total cases in the countries from which the trial recruited, i.e., 80% are non-  
180 white participants in the trial and 80% of the cases of diabetes in the country are in non-white  
181 ethnic groups. For this review, an ethnic group is considered to be underrepresented when the  
182 PPR is  $<0.80$ , and overrepresented when the PPR is  $>1.20$ . This assessment is consistent with a  
183 2020 study evaluating the participation of women in cardiovascular RCTs.<sup>9</sup>

184  
185 The numerator for the PPR was known for each trial. The denominator, however, was calculated  
186 for each trial using prevalence and demographic data. The denominator of the PPR represents the  
187 proportion of white and non-white people with T2DM based on prevalence and population data  
188 for the country or region. If these data were not available, we used an estimate of 14.8% white  
189 people and 85.2% non-white people as described in detail below. The proportion of non-white  
190 and white people worldwide was determined by assuming that all people in Europe, Canada, the  
191 United States, and Australia were white; this resulted in an estimate of 14.8% white people and  
192 85.2% non-white people. By estimating the “expected” cases for white people and non-white  
193 people, it is possible to calculate a PPR using the observed number of white and non-white  
194 participants in a trial and comparing this to the number one would expect to see if the trial  
195 recruited participants in proportion to the diabetes prevalence in ethnic groups for the  
196 country/region from which the trial recruited the greatest number of people. Appendix A  
197 provides a detailed explanation of PPR calculations. A list of estimates used for the PPR  
198 calculations is provided in eTable 4 in the Supplement.

199

200 Once the PPRs for white and non-white people were calculated for each trial, a random-effects  
201 meta-analysis was used to pool the individual-study PPRs and compute the overall 95%  
202 confidence intervals for the pooled PPRs. The random-effects model was used for this analysis  
203 because it provides appropriately wider confidence intervals and study weights in the presence of  
204 heterogeneity, which we expected to see across trial conditions and countries of conduct.  
205 Because this review is not focused on the clinical outcomes of the trials, but rather on the  
206 recruitment strategy, the random-effects estimate is preferable. Under this model, it can be  
207 assumed that the true PPR may differ according to the setting, country, or type of trial.

208  
209 We conducted a sensitivity analysis by perturbing the 14.8% white and 85.2% non-white  
210 assumption when data on expected prevalence in studies for which this was not available. We  
211 systematically altered the prevalence of non-whites to values from 80 through 90% by  
212 increments of 5%, and of white participants from 10% through 20% by increments of 5%.

213  
214 All study-specific PPR estimates were calculated in Microsoft Excel, and the pooled PPRs across  
215 studies along with the 95% confidence intervals were calculated using Review Manager version  
216 5.4 (RevMan).

217

## 218 **Results**

219 Of the 573 records that were assessed for eligibility following removal of duplicates, 82 RCTs  
220 with a total of 296 964 participants were included (eFigure 1 in the Supplement). The list of  
221 included RCTs is provided in Table 2. The RCTs that were excluded after full-text review are  
222 provided in eTable 3 in the Supplement. Of the 82 trials included in the review, 82.9% were

223 sponsored by industry,<sup>10-77</sup> and 17.1% were government-funded,<sup>78-91</sup> and most studies (63.4%)  
224 were published between the years 2011-2020. The proportion of non-white participants in this set  
225 of trials increased significantly from 10.9% in the years 2000-2005 to 23.8% between 2006-2011  
226 and remained relatively constant between 2006-2020. Over one-third of the studies in the review  
227 (39.0%) recruited the greatest number of participants from the United States, and the most  
228 proportional recruitment of non-white populations occurred in trials that recruited primarily from  
229 North America (31.9%) and the United States (26.4%). The most common pharmacotherapy  
230 interventions were from the GLP-1 agonist, SGLT-2 inhibitor, and DPP-4 inhibitor classes. The  
231 percentage of non-white participants across all trials was 23.4%. Government-funded trials had a  
232 higher overall percentage of non-white participants (25.3%) than industry-funded studies  
233 (23.1%) (Table 1).

234  
235 The pooled PPR for the white group is 2.19 (95%CI: 1.91, 2.50) for industry trials, consistent  
236 with overrepresentation, and 1.11 (95%CI: 1.00, 1.23) in government trials, consistent with  
237 proportional representation. The PPR for non-white ethnic group(s) is 0.33 (95%CI: 0.29, 0.38)  
238 for industry trials, and 0.73 (95%CI: 0.62, 0.86) for government trials, both consistent with  
239 underrepresentation (Figure 1).

240

### 241 **Sensitivity Analysis**

242 Nineteen industry-funded trials in this review did not provide country or region-specific data  
243 indicating from where participants were recruited.<sup>10-13,19,22,27,39,54-57,63,68-71,75,77</sup> For these trials, the  
244 worldwide proportion of white and non-white people was estimated by assuming that all people  
245 in Europe, Canada, the United States, and Australia were white; this resulted in an estimate of

246 14.8% white people and 85.2% non-white people. A series of sensitivity analyses that varied the  
247 estimated proportion of white and non-white people for these seven trials in which we imputed  
248 these values was conducted. The proportion of white participants was varied from 80% through  
249 90%; and of non-white participants, from 10% through 20%. These did not result in appreciably  
250 different estimates from the main analyses. The full data for these sensitivity analyses are shown  
251 in Appendix B.

252

### 253 **Discussion**

254 T2DM disproportionately affects non-white populations worldwide.<sup>92</sup> The objective of this meta-  
255 analysis was to document the underrepresentation of non-white ethnic participants in large RCTs  
256 of T2DM therapies, and to investigate the differences in ethnic representation between industry-  
257 funded trials and government-funded trials. This analysis shows that white individuals are over-  
258 enrolled, and non-white individuals are under-enrolled in diabetes RCTs. Government-funded  
259 T2DM trials tend to have better representation of non-white participants than do industry-funded  
260 trials.

261

262 The finding that government-funded trials recruit more diverse participants may reflect  
263 adherence to the more stringent funding conditions associated with accepting funding from  
264 government bodies. For example, the NIH emphasizes the inclusion and appropriate  
265 representation of minority groups in clinical research.<sup>4</sup> This measure attempts to ensure that  
266 visible minority populations are more proportionately represented in NIH-funded clinical  
267 research, and that research findings are generalizable across all ethnic groups. Industry-funded

268 trials do not have the same requirements as the NIH, and therefore, control over recruitment is  
269 held entirely by the trial Steering Committee, sponsor, and research staff.

270

271 Issues with diverse representation extend beyond RCTs of T2DM. Underrepresentation of non-  
272 white populations was apparent in 2020 COVID-19 trials as well.<sup>93</sup> Non-white populations,  
273 specifically Black, Native Americans, and LatinX people were disproportionately impacted by  
274 COVID-19, however, they were inadequately represented in remdesivir clinical trials.<sup>93</sup> The  
275 underrepresentation of non-white participants limits the ability to generalize results and safety  
276 outcomes for all ethnic groups and may limit the update of this evidence by the non-white ethnic  
277 communities, which adds to the disadvantages they face.

278

279 For industry trials, white participants tend to be overrepresented relative to their disease burden  
280 (Figure 2a). However, this estimate was heterogenous. For example, some studies had PPR  
281 values that were significantly higher than the others (i.e., > 1.78).<sup>10-13,19,22,27,39,54-57,63,68-71,75,77</sup>  
282 This is because these RCTs did not provide country or region-specific data regarding from where  
283 participants were recruited. As such, worldwide estimates were determined for both prevalence  
284 and demographic data. Prevalence estimates were obtained from Saeedi et al<sup>94</sup> and are listed in  
285 eTable 4 in the Supplement. The worldwide white and non-white population proportion  
286 estimates do not necessarily reflect the demographics of where participants were recruited for  
287 these studies. Therefore, the PPRs for white participants in industry trials are likely  
288 overestimates, however, our results were not seriously sensitive to altering this assumption  
289 (Appendix B). This is because the proportion of non-white participants in these trials was  
290 relatively small, and therefore the varying worldwide proportion estimates did not greatly affect

291 the pooled PPR. Greater variance was observed among the different proportions of white  
292 participants in the trials. Overall, the effects of the varying worldwide proportions of both white  
293 and non-white people on the PPRs were limited. This is because estimates were only altered for  
294 19 out of the 68 industry trials and the participants in all 19 trials only comprise 7.6% of the total  
295 participants across the industry-funded trials in this review.

296  
297 Non-white participants tended to be underrepresented in industry-funded trials relative to their  
298 disease burden (Figure 4). Trials such as EXSCEL<sup>24</sup>, REWIND<sup>20</sup>, RENAAL<sup>53</sup>, EMPA-REG  
299 OUTCOME<sup>45</sup>, and ALTITUDE<sup>32</sup> represent outliers to this trend with non-white PPRs of 1.04,  
300 1.06, 1.15, 1.18, and 1.85, respectively. These trials all recruited over 1500 participants from at  
301 least 24 countries including regions of North America, Europe, South America, Asia, and Africa.  
302 Future industry-funded trials should consider enrolling participants from diverse communities  
303 and regions of the world especially when the disease burden is higher than in white European  
304 origin individuals and regions where white Europeans are the majority.

305  
306 The potential explanations for the patterns of overrepresentation of white participants and  
307 underrepresentation of non-white participants are as follows: first, inclusion and exclusion  
308 criteria of RCTs may favour enrolling white participants over non-white participants. For  
309 example, specialty clinics and hospitals where research is taking place may be located in areas  
310 with lower proportions of non-white patients, affecting the overall diversity of participants in  
311 RCTs. Second, limited screening of non-white individuals for enrollment may occur because of  
312 possible implicit biases, and social or medical reasons that make their participation difficult;  
313 third, distrust and fear of medical institutions due to historical mistreatment of minority groups

314 may result in a lack of willingness of non-white people to participate in clinical trials; fourth,  
315 minority groups may not enrol because of language barriers, cultural practices or related  
316 contextual factors that limit their participation, including socioeconomic disadvantage; fifth,  
317 logistical barriers may exist such as inflexible work schedules and additional costs associated  
318 with participating in research studies such as costs of public transportation and/or fuel.<sup>93</sup>

319  
320 Furthermore, the lack of diversity among Principal Investigators, local investigators, and study  
321 staff of some RCTs may also be related to the lower enrolment of non-white participants.<sup>93</sup> For  
322 example, in an NIH study on the diversity of the NIH-funded workforce, it was found that 71.9%  
323 of principal investigators on NIH-funded research project grants were white.<sup>95</sup> Diverse  
324 representation among the study staff might increase the confidence of participants from minority  
325 communities and improve communication.<sup>93</sup> Additionally, industry-funded trials could  
326 potentially benefit from having ethnic participant recruitment guidelines similar to the ones that  
327 exist for the NIH. Regulatory bodies could indicate that proportional representation of  
328 participants affected by the disease of interest by ethnicity is strongly recommended or  
329 mandatory such that industry trial leaders will more carefully consider who and from where to  
330 recruit within a given country or region. Future reviews of ethnic participant recruitment should  
331 be completed for trials that were conducted within a single country to assess country-specific  
332 trends. These reviews could guide clinical practice and be used to establish recruitment standards  
333 that are reasonable given the prevalence of T2DM, and demographics in a given country. Future  
334 studies should also be conducted to analyze ethnic participant recruitment trends in RCTs for  
335 other health conditions which are known to be common in non-white populations such as  
336 hypertension and stroke.

337  
338 Our study has several strengths. The meta-analysis included trials that were published in journals  
339 with high impact factors ( $\geq 30$  for industry trials,  $\geq 10$  for government), which are likely to be  
340 highly cited and used to inform clinical guidelines. Analyzing ethnic participant recruitment in  
341 these studies allows for a finer assessment of the generalizability of the results of these studies to  
342 certain practice settings. The calculation and presentation of the PPR metric improves the  
343 summary of the findings of overrepresentation and underrepresentation of white and non-white  
344 participants (Figure 2a; Figure 2b; Figure 3a; Figure 3b).

345  
346 Our study has certain limitations. First, the PPR denominator calculations were based on  
347 prevalence and demographic data for white and non-white participants in different countries and  
348 regions of the world. While T2DM prevalence and demographic data are typically documented  
349 for specific countries, limited data exist for T2DM prevalence and demographics in larger  
350 regions of the world. When specific data were not available, these values were estimated using a  
351 standardized algorithm. Second, this meta-analysis only included studies that were published on  
352 January 1, 2000, and onwards. However, our estimates of the prevalence and demographic data  
353 do not correspond to the prevalence of T2DM in white and non-white people and the ethnic  
354 breakdown of countries or regions at the time that each trial was conducted, although we  
355 attempted to match them as closely as possible. Finally, our pooled meta-analytic estimates had  
356 high heterogeneity (I-squared  $> 90\%$ ). This heterogeneity may stem from many factors, including  
357 study design, country or region of conduct, study size, or dates of enrolment. However, despite  
358 this, our results were consistent with respect to direction. Only 6 of 68 industry trials had  $PPR < 1$   
359 for white people and  $PPR > 1$  for non-white people, and these carried 9.6% of the weight in the

360 pooled estimates, and only 5 of 14 government trials had PPR <1 for white people, and >1 for  
361 non-white people, and these carried 18.0% of the weight in the pooled estimates. Thus, statistical  
362 heterogeneity influenced the precision of our estimates, but not the direction or magnitude to an  
363 extent that would cause concern. Finally, we did not conduct risk of bias assessments for the  
364 trials used in this review. Our selection criteria were such that we only included large (n>100)  
365 randomized trials (lowest risk of bias design) published in high-impact journals, which helps  
366 ensure comparable, and low risk of bias across included studies.

367 **Conclusion**

368 This review examined the representation of white and non-white populations in T2DM RCTs.  
369 Non-white participants appear to be underrepresented in both industry and government-funded  
370 T2DM trials relative to their disease burden, while white participants appear to be  
371 overrepresented. The systematic review shows that the greatest disparity in diversity between the  
372 groups in RCTs occurs in industry-funded trials. Strategies to improve recruitment and  
373 enrolment of diverse populations into international industry and government-funded RCTs  
374 should be explored.

375 **Acknowledgements:** Dr. Anand holds a Canada Research Chair in Ethnic Diversity and  
376 Cardiovascular Disease (Tier 1) and Michael G DeGroot Heart and Stroke Chair in Population  
377 Health.

378 We thank Justin Wu (McMaster University) for his assistance with extracting data and creating  
379 summary tables.

### 380 **Disclosures**

381 Dr. de Souza has served as an external resource person to the World Health Organization's  
382 Nutrition Guidelines Advisory Group on trans fats, saturated fats, and polyunsaturated fats. The  
383 WHO paid for his travel and accommodation to attend meetings from 2012-2017 to present and  
384 discuss this work. He has also done contract research for the Canadian Institutes of Health  
385 Research's Institute of Nutrition, Metabolism, and Diabetes, Health Canada, and the World  
386 Health Organization for which he received remuneration. He has received speaker's fees from  
387 the University of Toronto, and McMaster Children's Hospital. He has held grants from the  
388 Canadian Institutes of Health Research, Canadian Foundation for Dietetic Research, Population  
389 Health Research Institute, and Hamilton Health Sciences Corporation as a principal investigator,  
390 and is a co-investigator on several funded team grants from the Canadian Institutes of Health  
391 Research. He serves as a member of the Nutrition Science Advisory Committee to Health  
392 Canada (Government of Canada), and a co-opted member of the Scientific Advisory Committee  
393 on Nutrition (SACN) Subgroup on the Framework for the Evaluation of Evidence, and as an  
394 independent director of the Helderleigh Foundation (Canada). All other authors declare no  
395 conflicts of interest.

396 **Registration and Protocol:** This study has been registered into an embargo on Open Science  
397 Framework (OSF) under the name: Assessing participation of non-white people in type 2  
398 diabetes mellitus randomized clinical trials: A Meta-Analysis. A protocol was not prepared.

399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421

## References

1. Oldroyd J, Banerjee M, Heald A, Cruickshank K. Diabetes and ethnic minorities. *Postgrad Med J*. 2005;81(958):486-490. doi:10.1136/pgmj.2004.029124
2. Hariton E, Locascio JJ. Randomised controlled trials—the gold standard for effectiveness research. *BJOG*. 2018;125(13):1716. doi:10.1111/1471-0528.15199
3. Khan SU, Khan MZ, Raghu Subramanian C, et al. Participation of women and older participants in randomized clinical trials of lipid-lowering therapies: a systematic review. *JAMA Netw Open*. 2020;3(5):e205202. doi:10.1001/jamanetworkopen.2020.5202
4. Inclusion of women and minorities as participants in research involving human subjects | grants. Nih. Gov. Accessed April 1, 2021. <https://grants.nih.gov/policy/inclusion/women-and-minorities.htm>
5. Treweek S, Forouhi NG, Narayan KMV, Khunti K. COVID-19 and ethnicity: who will research results apply to? *Lancet*. 2020;395(10242):1955-1957. doi:10.1016/S0140-6736(20)31380-5
6. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Guidelines for Good Clinical Practice. ICH. November 9, 2016. Accessed April 1, 2021. [https://database.ich.org/sites/default/files/E6\\_R2\\_Addendum.pdf](https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf).
7. Health Canada. Guidance for industry: standards for clinical trials in type 2 diabetes in Canada. Health Canada. Published July 10, 2006. Accessed April 1, 2021. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/clinical-trials/guidance-industry-standards-clinical-trials-type-2-diabetes-canada.htm>

- 422 8. Department of health | clinical trials. Australian Government Department of Health.  
423 Accessed April 1, 2021.  
424 <https://www1.health.gov.au/internet/main/publishing.nsf/Content/Clinical-Trials>
- 425 9. Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women's participation  
426 in cardiovascular clinical trials from 2010 to 2017. *Circulation*. 2020;141(7):540-548.  
427 doi:10.1161/CIRCULATIONAHA.119.043594
- 428 10. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the  
429 Diabetes Atherosclerosis Intervention Study, a randomised study. *Lancet*.  
430 2001;357(9260):905-910. doi:10.1016/S0140-6736(00)04209-4
- 431 11. Barnett AH, Huisman H, Jones R, Eynatten M von, Patel S, Woerle HJ. Linagliptin for  
432 patients aged 70 years or older with type 2 diabetes inadequately controlled with common  
433 antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. *Lancet*.  
434 2013;382(9902):1413-1423. doi:10.1016/S0140-6736(13)61500-7
- 435 12. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once  
436 weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type  
437 2 diabetes (DURATION-2): a randomised trial. *Lancet*. 2010;376(9739):431-439.  
438 doi:10.1016/S0140-6736(10)60590-9
- 439 13. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in  
440 type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled  
441 trial. *Lancet*. 2012;379(9824):1403-1411. doi:10.1016/S0140-6736(11)61879-5
- 442 14. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin  
443 in type 2 diabetes. *NEJM*. 2020;383(15):1425-1435. doi:10.1056/NEJMoa2004967

- 444 15. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus  
445 glimepiride in patients with type 2 diabetes inadequately controlled with metformin  
446 (Cantata-su): 52 week results from a randomised, double-blind, phase 3 non-inferiority  
447 trial. *Lancet*. 2013;382(9896):941-950. doi:10.1016/S0140-6736(13)60683-2
- 448 16. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among  
449 patients with type 2 diabetes: the scale diabetes randomized clinical trial. *JAMA*.  
450 2015;314(7):687-699. doi:10.1001/jama.2015.9676
- 451 17. de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and  
452 stage 4 chronic kidney disease. *NEJM*. 2013;369(26):2492-2503.  
453 doi:10.1056/NEJMoa1306033
- 454 18. Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP  
455 and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-  
456 controlled and active comparator-controlled phase 2 trial. *Lancet*. 2018;392(10160):2180-  
457 2193. doi:10.1016/S0140-6736(18)32260-8
- 458 19. Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin  
459 compared with glimepiride in patients with type 2 diabetes inadequately controlled on  
460 metformin: a randomised, double-blind, non-inferiority trial. *Lancet*.  
461 2012;380(9840):475-483. doi:10.1016/S0140-6736(12)60691-6
- 462 20. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes  
463 in type 2 diabetes (Rewind): a double-blind, randomised placebo-controlled trial. *Lancet*.  
464 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3
- 465 21. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular  
466 outcomes in type 2 diabetes. *NEJM*. 2015;373(3):232-242. doi:10.1056/NEJMoa1501352

- 467 22. Heerspink HJL, Parving HH, Andress DL, et al. Atrasentan and renal events in patients  
468 with type 2 diabetes and chronic kidney disease (Sonar): a double-blind, randomised,  
469 placebo-controlled trial. *Lancet*. 2019;393(10184):1937-1947. doi:10.1016/S0140-  
470 6736(19)30772-X
- 471 23. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes  
472 in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a  
473 double-blind, randomised placebo-controlled trial. *Lancet*. 2018;392(10157):1519-1529.  
474 doi:10.1016/S0140-6736(18)32261-X
- 475 24. Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on  
476 cardiovascular outcomes in type 2 diabetes. *NEJM*. 2017;377(13):1228-1239.  
477 doi:10.1056/NEJMoa1612917
- 478 25. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular  
479 outcomes in patients with type 2 diabetes. *NEJM*. 2019;381(9):841-851.  
480 doi:10.1056/NEJMoa1901118
- 481 26. Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aloglitazar on cardiovascular  
482 outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the  
483 alecardio randomized clinical trial. *JAMA*. 2014;311(15):1515-1525.  
484 doi:10.1001/jama.2014.3321
- 485 27. Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration  
486 vs insulin degludec/liraglutide on glycosylated hemoglobin levels in patients with  
487 uncontrolled type 2 diabetes: the dual v randomized clinical trial. *JAMA*.  
488 2016;315(9):898-907. doi:10.1001/jama.2016.1252

- 489 28. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular  
490 outcomes in type 2 diabetes. *NEJM*. 2016; 375:311-322. doi:10.1056/NEJMoa1603827
- 491 29. Marso SP, McGuire DK, Zinman B, et al. Efficacy and safety of degludec versus glargine  
492 in type 2 diabetes. *NEJM*. 2017;377(8):723-732. doi:10.1056/NEJMoa1615692
- 493 30. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal  
494 events in type 2 diabetes. *NEJM*. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925
- 495 31. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on  
496 progression of coronary atherosclerosis in patients with type 2 diabetes: the periscope  
497 randomized controlled trial. *JAMA*. 2008;299(13):1561-1573.  
498 doi:10.1001/jama.299.13.1561
- 499 32. Parving HH, Brenner BM, McMurray JJV, et al. Cardiorenal end points in a trial of  
500 aliskiren for type 2 diabetes. *NEJM*. 2012;367(23):2204-2213.  
501 doi:10.1056/NEJMoa1208799
- 502 33. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2  
503 diabetes and nephropathy. *NEJM*. 2019;380(24):2295-2306.  
504 doi:10.1056/NEJMoa1811744
- 505 34. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and  
506 acute coronary syndrome. *NEJM*. 2015;373(23):2247-2257.  
507 doi:10.1056/NEJMoa1509225
- 508 35. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and  
509 placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.  
510 *Lancet*. 2019;394(10192):39-50. doi:10.1016/S0140-6736(19)31271-1

- 511 36. Ray KK, Nicholls SJ, Buhr KA, et al. Effect of apabetalone added to standard therapy on  
512 major adverse cardiovascular events in patients with recent acute coronary syndrome and  
513 type 2 diabetes: a randomized clinical trial. *JAMA*. 2020;323(16):1565-1573.  
514 doi:10.1001/jama.2020.3308
- 515 37. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs  
516 sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with  
517 metformin alone or with sulfonylurea: the pioneer 3 randomized clinical trial. *JAMA*.  
518 2019;321(15):1466-1480. doi:10.1001/jama.2019.2942
- 519 38. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major  
520 cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal  
521 risk: the carmelina randomized clinical trial. *JAMA*. 2019;321(1):69-79.  
522 doi:10.1001/jama.2018.18269
- 523 39. Scheen AJ, Finer N, Hollander P, Jensen MD, Gaal LFV. Efficacy and tolerability of  
524 rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled  
525 study. *Lancet*. 2006;368(9548):1660-1672. doi:10.1016/S0140-6736(06)69571-8
- 526 40. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in  
527 patients with type 2 diabetes mellitus. *NEJM*. 2013;369:1317-1326  
528 doi:10.1056/NEJMoa1307684
- 529 41. Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of  
530 retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled  
531 trial. *The Lancet*. 2008;372(9647):1385-1393. doi:10.1016/S0140-6736(08)61411-7
- 532 42. Steg PG, Bhatt DL, Simon T, et al. Ticagrelor in patients with stable coronary disease  
533 and diabetes. *NEJM*. Published online September 1, 2019. doi:10.1056/NEJMoa1908077

- 534 43. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in  
535 patients with type 2 diabetes. *NEJM*. 2013;369(14):1327-1335.  
536 doi:10.1056/NEJMoa1305889
- 537 44. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type  
538 2 diabetes. *NEJM*. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389
- 539 45. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and  
540 mortality in type 2 diabetes. *NEJM*. 2015;373(22):2117-2128.  
541 doi:10.1056/NEJMoa1504720
- 542 46. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with  
543 type 2 diabetes who have inadequate glycaemic control with metformin: a randomised,  
544 double-blind, placebo-controlled trial. *The Lancet*. 2010;375(9733):2223-2233.  
545 doi:10.1016/S0140-6736(10)60407-2
- 546 47. Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients  
547 with diabetic nephropathy: a randomized clinical trial. *JAMA*. 2015;314(9):884-894.  
548 doi:10.1001/jama.2015.10081
- 549 48. Bakris GL, Pitt B, Weir MR, et al. Effect of patiromer on serum potassium level in  
550 patients with hyperkalemia and diabetic kidney disease: the amethyst-dn randomized  
551 clinical trial. *JAMA*. 2015;314(2):151. doi:10.1001/jama.2015.7446
- 552 49. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-  
553 enzyme inhibition in type 2 diabetes and nephropathy. *New England Journal of Medicine*.  
554 2004;351(19):1952-1961. doi:10.1056/NEJMoa042274

- 555 50. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic  
556 kidney disease. *New England Journal of Medicine*. 2021;384(2):129-139.  
557 doi:10.1056/NEJMoa2030186
- 558 51. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent  
559 worsening heart failure. *New England Journal of Medicine*. 2021;384(2):117-128.  
560 doi:10.1056/NEJMoa2030183
- 561 52. Blonde L, Jendle J, Gross J, et al. Once-weekly dulaglutide versus bedtime insulin  
562 glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes  
563 (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. *The Lancet*.  
564 2015;385(9982):2057-2066. doi:10.1016/S0140-6736(15)60936-9
- 565 53. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and  
566 cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *New England*  
567 *Journal of Medicine*. 2001;345(12):861-869. doi:10.1056/NEJMoa011161
- 568 54. Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in  
569 patients with type 2 diabetes (DURATION-6): a randomised, open-label study. *The*  
570 *Lancet*. 2013;381(9861):117-124. doi:10.1016/S0140-6736(12)61267-7
- 571 55. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day  
572 for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial  
573 (LEAD-6). *The Lancet*. 2009;374(9683):39-47. doi:10.1016/S0140-6736(09)60659-0
- 574 56. Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J.  
575 Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on  
576 glycemic control in patients with type 2 diabetes: a randomized clinical trial. *JAMA*.  
577 2017;318(15):1460-1470. doi:10.1001/jama.2017.14752

- 578 57. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin  
579 glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label  
580 randomised trial. *The Lancet*. 2010;375(9733):2234-2243. doi:10.1016/S0140-  
581 6736(10)60406-0
- 582 58. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular  
583 events in patients with type 2 diabetes in the PROactive Study (Prospective pioglitazone  
584 clinical trial in macrovascular events): a randomised controlled trial. *The Lancet*.  
585 2005;366(9493):1279-1289. doi:10.1016/S0140-6736(05)67528-9
- 586 59. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the  
587 treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. *The Lancet*.  
588 2008;372(9645):1240-1250. doi:10.1016/S0140-6736(08)61206-4
- 589 60. Dungan KM, Povedano ST, Forst T, et al. Once-weekly dulaglutide versus once-daily  
590 liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised,  
591 open-label, phase 3, non-inferiority trial. *The Lancet*. 2014;384(9951):1349-1357.  
592 doi:10.1016/S0140-6736(14)60976-4
- 593 61. Gallwitz B, Guzman J, Dotta F, et al. Exenatide twice daily versus glimepiride for  
594 prevention of glycaemic deterioration in patients with type 2 diabetes with metformin  
595 failure (Eurexa): an open-label, randomised controlled trial. *The Lancet*.  
596 2012;379(9833):2270-2278. doi:10.1016/S0140-6736(12)60479-6
- 597 62. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type  
598 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-  
599 treatment trial. *The Lancet*. 2009;373(9662):473-481. doi:10.1016/S0140-  
600 6736(08)61246-5

- 601 63. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin,  
602 versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1  
603 diabetes (Begin basal-bolus type 1): a phase 3, randomised, open-label, treat-to-target  
604 non-inferiority trial. *The Lancet*. 2012;379(9825):1489-1497. doi:10.1016/S0140-  
605 6736(12)60204-9
- 606 64. Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of  
607 microalbuminuria in type 2 diabetes. *New England Journal of Medicine*.  
608 2011;364(10):907-917. doi:10.1056/NEJMoa1007994
- 609 65. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin  
610 to oral therapy in type 2 diabetes. *New England Journal of Medicine*. 2007;357(17):1716-  
611 1730. doi:10.1056/NEJMoa075392
- 612 66. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular  
613 outcomes — an interim analysis. *New England Journal of Medicine*. 2007;357(1):28-38.  
614 doi:10.1056/NEJMoa073394
- 615 67. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin,  
616 or glyburide monotherapy. *N Engl J Med*. 2006;355(23):2427-2443.  
617 doi:10.1056/NEJMoa066224
- 618 68. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-  
619 receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *New*  
620 *England Journal of Medicine*. 2001;345(12):851-860. doi:10.1056/NEJMoa011303
- 621 69. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in  
622 patients with type 2 diabetes. *New England Journal of Medicine*. 2016;375(19):1834-  
623 1844. doi:10.1056/NEJMoa1607141

- 624 70. Matthews DR, Paldánus PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic  
625 durability of an early combination therapy with vildagliptin and metformin versus  
626 sequential metformin monotherapy in newly diagnosed type 2 diabetes (Verify): a 5-year,  
627 multicentre, randomised, double-blind trial. *The Lancet*. 2019;394(10208):1519-1529.  
628 doi:10.1016/S0140-6736(19)32131-2
- 629 71. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The  
630 effect of irbesartan on the development of diabetic nephropathy in patients with type 2  
631 diabetes. *New England Journal of Medicine*. 2001;345(12):870-878.  
632 doi:10.1056/NEJMoa011489
- 633 72. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with  
634 losartan in type 2 diabetes and nephropathy. *New England Journal of Medicine*.  
635 2008;358(23):2433-2446. doi:10.1056/NEJMoa0708379
- 636 73. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes  
637 and chronic kidney disease. *New England Journal of Medicine*. 2009;361(21):2019-2032.  
638 doi:10.1056/NEJMoa0907845
- 639 74. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type  
640 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week,  
641 randomised, parallel-group, open-label trial. *The Lancet*. 2010;375(9724):1447-1456.  
642 doi:10.1016/S0140-6736(10)60307-8
- 643 75. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin  
644 glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised  
645 trial. *The Lancet*. 2010;375(9733):2244-2253. doi:10.1016/S0140-6736(10)60632-0

- 646 76. Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldánus PM. Individualised  
647 treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or  
648 lone therapy (Interval): a 24 week, randomised, double-blind, placebo-controlled  
649 study. *The Lancet*. 2013;382(9890):409-416. doi:10.1016/S0140-6736(13)60995-2
- 650 77. Zinman B, Fulcher G, Rao PV, et al. Insulin degludec, an ultra-long-acting basal insulin,  
651 once a day or three times a week versus insulin glargine once a day in patients with type  
652 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet*.  
653 2011;377(9769):924-931. doi:10.1016/S0140-6736(10)62305-7
- 654 78. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular  
655 disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes  
656 Study (Cards): multicentre randomised placebo-controlled trial. *Lancet*.  
657 2004;364(9435):685-696. doi:10.1016/S0140-6736(04)16895-5
- 658 79. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with  
659 type 2 diabetes mellitus (The field study): randomised controlled trial. *Lancet*.  
660 2005;366(9500):1849-1861. doi:10.1016/S0140-6736(05)67667-2
- 661 80. Fayfman M, Galindo RJ, Rubin DJ, et al. A randomized controlled trial on the safety and  
662 efficacy of exenatide therapy for the inpatient management of general medicine and  
663 surgery patients with type 2 diabetes. *Diabetes Care*. 2019;42(3):450-456.  
664 doi:10.2337/dc18-1760
- 665 81. Goldfine AB, Fonseca V, Jablonski KA, et al. Salicylate (Salsalate) in patients with type  
666 2 diabetes. *Ann Intern Med*. 2013;159(1):1-12. doi:10.7326/0003-4819-159-1-  
667 201307020-00003

- 668 82. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of  
669 salsalate on glycemic control in patients with type 2 diabetes. *Ann Intern Med*.  
670 2010;152(6):346-357. doi:10.1059/0003-4819-152-6-201003160-00004
- 671 83. Effects of intensive glucose lowering in type 2 diabetes. *New England Journal of*  
672 *Medicine*. 2008;358(24):2545-2559. doi:10.1056/NEJMoa0802743
- 673 84. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the  
674 treatment of diabetic nephropathy. *New England Journal of Medicine*.  
675 2013;369(20):1892-1903. doi:10.1056/NEJMoa1303154
- 676 85. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic  
677 patients irrespective of the responsiveness to its antidiabetic effect. *Diabetes Care*.  
678 2003;26(9):2493-2499. doi:10.2337/diacare.26.9.2493
- 679 86. Tanamas SK, Saulnier PJ, Fufaa GD, et al. Long-term effect of losartan on kidney disease  
680 in american indians with type 2 diabetes: a follow-up analysis of a randomized clinical  
681 trial. *Diabetes Care*. 2016;39(11):2004-2010. doi:10.2337/dc16-0795
- 682 87. Vellanki P, Bean R, Oyedokun FA, et al. Randomized controlled trial of insulin  
683 supplementation for correction of bedtime hyperglycemia in hospitalized patients with  
684 type 2 diabetes. *Diabetes Care*. 2015;38(4):568-574. doi:10.2337/dc14-1796
- 685 88. Wexler DJ, Krause-Steinrauf H, Crandall JP, et al. Baseline characteristics of randomized  
686 participants in the glycemia reduction approaches in diabetes: a comparative  
687 effectiveness study(Grade). *Diabetes Care*. 2019;42(11):2098-2107. doi:10.2337/dc19-  
688 0901

- 689 89. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the U.K. Prospective  
690 Diabetes Study Group. Sulfonylurea inadequacy. *Diabetes Care*. 2002;25(2):330-336.  
691 doi:10.2337/diacare.25.2.330
- 692 90. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *New*  
693 *England Journal of Medicine*. 2009;360(24):2503-2515. doi:10.1056/NEJMoa0805796
- 694 91. Duckworth W, Abaira C, Moritz T, et al. Glucose control and vascular complications in  
695 veterans with type 2 diabetes. *N Engl J Med*. 2009;360(2):129-139.  
696 doi:10.1056/NEJMoa0808431
- 697 92. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204  
698 countries and territories, 1990–2019: a systematic analysis for the Global Burden of  
699 Disease Study 2019. *Lancet*. 2020;396(10258):1204-1222. doi:10.1016/S0140-  
700 6736(20)30925-9
- 701 93. Chastain DB, Osa SP, Henao-Martínez AF, Franco-Paredes C, Chastain JS, Young HN.  
702 Racial disproportionality in covid clinical trials. *NEJM*. 2020;383(9):e59.  
703 doi:10.1056/NEJMp2021971
- 704 94. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates  
705 for 2019 and projections for 2030 and 2045: Results from the International Diabetes  
706 Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract*. 2019;157:107843.  
707 doi:10.1016/j.diabres.2019.107843
- 708 95. New NIH study on diversity – NIH extramural nexus. Accessed December 5, 2021.  
709 <https://nexus.od.nih.gov/all/2011/08/18/new-nih-study-on-diversity/>

## 710 Tables

711 Table 1. Baseline Characteristics of the 52 Clinical Trials

Category	Number of Trials, N (%)	Number of Non-White Participants, N (%)
<b>Overall</b>	82	69,420 (23.4)
<b>Sponsor</b>		
Industry	68 (82.9)	60,331 (23.1)
Government	14 (17.1)	9089 (25.3)
<b>Publication Year</b>		
2000-2005	10 (12.2)	2535 (10.9)
2006-2010	20 (24.4)	8656 (23.8)
2011-2015	26 (31.7)	18733 (27.1)
2016-2020	26 (31.7)	35411 (23.1)
<b>Trial Size</b>		
Quartile 1 (100-500)	18 (22.0)	1620 (30.9)
Quartile 2 (501-1500)	23 (28.0)	3182 (17.1)
Quartile 3 (1501-5000)	19 (23.2)	11812 (21.9)
Quartile 4 (>5000)	22 (26.8)	52806 (23.3)
<b>Region of Greatest Recruitment</b>		
Global	19 (23.2)	4989 (25.0)
Europe	16 (19.5)	12393 (18.4)
North America	5 (6.1)	2428 (31.9)
North America and Europe	3 (3.7)	672 (12.0)

North America & South America	1 (1.2)	702 (12.1)
United States	32 (39.0)	45213 (26.4)
United Kingdom	2 (2.4)	702 (9.1)
Australia	1 (1.2)	702 (7.2)
Russia	1 (1.2)	83 (6.8)
Japan	1 (1.2)	136 (100)
Argentina	1 (1.2)	2403 (24.3)
<b>Pharmacotherapy Intervention</b>		
GLP-1 Agonists	15 (18.3)	13324 (22.1)
SGLT-2 Inhibitors	8 (9.8)	12104 (20.4)
DPP-4 Inhibitors	6 (7.3)	11670 (26.5)
Renin Inhibitors	1 (1.2)	3711 (15.8)
Bardoxolone Methyl	1 (1.2)	491 (22.5)
Antiplatelet Medication	1 (1.2)	5524 (28.7)
PPAR Modulator	1 (1.2)	2408 (33.3)
ETA Receptors	1 (1.2)	1558 (42.5)
BET Inhibitors	1 (1.2)	299 (12.4)
MR Antagonist	1 (1.2)	130 (15.8)
Darbepoetin Alfa	1 (1.2)	1468 (36.4)
CBI Antagonist	1 (1.2)	120 (11.5)
ACE inhibitor	1 (1.2)	411 (28.4)
Angiotensin Receptor Blockers	5 (6.1)	1037 (12.0)
Fibrates	2 (2.4)	720 (7.0)

Statins	1 (1.2)	162 (5.7)
Potassium Binder	1 (1.2)	0 (0)
Salicylates	2 (2.4)	185 (47.7)
Combination drugs	4 (4.9)	5213 (34.7)
Insulin	6 (7.3)	2507 (23.6)
Thiazolidinediones	2 (2.4)	210 (3.9)
Two or more classes of pharmacotherapies	20 (24.4)	6179 (21.1)

712 Abbreviations: GLP-1, glucagon-like peptide 1; SGLT-2, sodium-glucose transport protein 2; DPP-4, dipeptidyl  
713 peptidase 4; PPAR, peroxisome proliferator-activated receptor; ETA, endothelin receptor A; BET, bromodomain  
714 and extra-terminal; MR, mineralocorticoid; CB1, cannabinoid receptor type 1; ACE, Angiotensin-converting-  
715 enzyme

716

**Table 2. List of Randomized Clinical Trials Included in Systematic Review**

<b>Publication</b>	<b>Author</b>	<b>Year</b>	<b>Journal</b>	<b>Pharmacotherapy Intervention</b>	<b>Number of Participants</b>	<b>Females No. (%)</b>	<b>White Participants No. (%)</b>	<b>Non-White Participants No. (%)</b>
DAIS	DAIS Investigators	2001	Lancet	Fenofibrate	418	113 (27.0)	400 (95.7)	18 (4.3)
Barnett et al	Barnett et al	2013	Lancet	Linagliptin	241	76 (31.5)	233 (96.7)	8 (3.3)
DURATION-2	Bergental et al	2010	Lancet	Exenatide, Sitagliptin, Pioglitazone	491 <sup>a</sup>	237 (48.3)	168 (34.2)	323 (65.8)
Burant et al	Burant et al	2012	Lancet	TAK-875, Glimepiride, Placebo	426	223 (52.4)	352 (82.6)	74 (17.4)
VERTIS CV	Cannon et al	2020	NEJM	Ertugliflozin	8246	2477 (30.0)	7240 (87.8)	1006 (12.2)
CANTATA- SU	Cefalu et al	2013	Lancet	Canagliflozin, Glimepiride	1450	694 (47.9)	978 (67.5)	472 (32.5)
CARDS	Colhoun et al	2004	Lancet	Atorvastatin	2838	909 (32.0)	2676 (94.3)	162 (5.7)
SCALE	Davies et al	2015	JAMA	Liraglutide	846	421 (49.8)	705 (83.3)	141 (16.7)

BEACON	de Zeeuw et al	2013	NEJM	Bardoxolone methyl	2185	934 (42.8)	1694 (77.5)	491 (22.5)
Frias et al	Frias et al	2018	Lancet	LY3298176	316 <sup>b</sup>	148 (46.8)	253 (80.1)	63 (19.9)
Gallwitz et al	Gallwitz et al	2012	Lancet	Linagliptin, Glimepiride	1551 <sup>c</sup>	618 (39.9)	1319 (85.0)	232 (15.0)
REWIND	Gerstein et al	2019	Lancet	Dulaglutide	9901	4589 (46.4)	7498 (75.7)	2403 (24.3)
TECOS	Green et al	2015	NEJM	Sitagliptin	14671	4297 (29.3)	9957 (67.9)	4714 (32.1)
SONAR	Heerspink et al	2019	Lancet	Atrasentan	3668	946 (25.8)	2110 (57.5)	1558 (42.5)
Harmony Outcomes	Hernandez et al	2018	Lancet	Albiglutide	9463	2894 (30.6)	8030 (84.9)	1433 (15.1)
EXSCEL	Holman et al	2017	NEJM	Exenatide	14752	5603 (38.0)	11175 (75.8)	3577 (24.2)
PIONEER-6	Husain et al	2019	NEJM	Semaglutide	3183	1007 (31.6)	2300 (72.3)	883 (27.7)
FIELD	Keech et al	2005	Lancet	Fenofibrate	9795	3657 (37.3)	9093 (92.8)	702 (7.2)
AleCardio	Lincoff et al	2014	JAMA	Aleglitazar	7226	1966 (27.2)	4818 (66.7)	2408 (33.3)
DUAL V	Lingvay et al	2016	JAMA	Glargine, Liraglutide	557	277 (49.7)	527 (94.6)	30 (5.4)
LEADER	Marso et al	2016	NEJM	Liraglutide	9340	3337 (35.7)	7238 (77.5)	2102 (22.5)

DEVOTE	Marso et al	2017	NEJM	Insulin degludec, insulin glargine	7637	2859 (37.4)	5775 (75.6)	1862 (24.4)
CANVAS	Neal et al	2017	NEJM	Canagliflozin	10142	3633 (35.8)	7944 (78.3)	2198 (21.7)
PERISCOPE	Nissen et al	2008	JAMA	Pioglitazone, Glimepiride	543	177 (32.6)	445 (82.0)	98 (18.0)
ALTITUDE	Parving et al	2012	NEJM	Aliskiren	8561	2735 (32.0)	4850 (56.7)	3711 (43.3)
CREDESCENCE	Perkovic et al	2019	NEJM	Canagliflozin	4401	1494 (34.0)	2931 (66.6)	1470 (33.4)
ELIXA	Pfeffer et al	2015	NEJM	Lixisenatide	6068	1861 (30.7)	4576 (75.4)	1492 (24.6)
PIONEER-4	Pratley et al	2019	Lancet	Semaglutide, Liraglutide	711	341 (48.0)	519 (73.0)	192 (27.0)
Ray et al	Ray et al	2020	JAMA	Apabetalone	2418 <sup>d</sup>	618 (25.6)	2119 (87.6)	299 (12.4)
PIONEER 3	Rosenstock et al	2019	JAMA	Semaglutide, Sitagliptin	1864	879 (47.2)	1324 (71.0)	540 (29.0)
CARMELINA	Rosenstock et al	2019	JAMA	Linagliptin	6979	2589 (37.1)	5596 (80.2)	1383 (19.8)
RIO-Diabetes	Scheen et al	2006	Lancet	Rimonabant	1045	532 (50.9)	925 (88.5)	120 (11.5)
SAVOR-TIMI 53	Scirica et al	2013	NEJM	Saxagliptin	16492	5455 (33.1)	12407 (75.2)	4085 (24.8)

DIRECT-Protect 2	Sjolie et al	2008	Lancet	Candesartan	1905	957 (50.2)	1830 (96.1)	75 (3.9)
THEMIS	Steg et al	2019	NEJM	Ticagrelor	19220	6031 (31.4)	13696 (71.3)	5524 (28.7)
EXAMINE	White et al	2013	NEJM	Alogliptin	5380	1729 (32.1)	3909 (72.7)	1471 (27.3)
DECLARE-TIMI 58	Wiviott et al	2019	NEJM	Dapagliflozin, Placebo	17160	6422 (37.4)	13652 (79.6)	3507 (20.4)
EMPA-REG Outcome	Zinman et al	2015	NEJM	Empagliflozin	7020	2004 (28.6)	5081 (72.4)	1939 (27.6)
Fayfman et al	Fayfman et al	2019	Diabetes Care	Exenatide	150	74 (49.3)	41 (27.3)	109 (72.7)
TINSAL-T2D II	Goldfine et al	2013	Ann Intern Med	Salsalate	286	130 (45.5)	151 (52.8)	135 (47.2)
TINSAL-T2D	Goldfine et al	2010	Ann Intern Med	Salsalate	108	45 (41.7)	55 (50.9)	53 (49.1)
BARI 2D	Frye et al	2009	NEJM	Insulin providing drugs vs insulin sensitizing drugs	2368	702 (29.7)	1561 (65.9)	807 (34.1)

ACCORD	Gerstein et al	2008	NEJM	Intense (A1c <6) vs standard therapy	10251	3952 (38.6)	6604 (64.4)	3647 (35.6)
Bailey et al	Bailey et al	2010	Lancet	Dapagliflozin	546	254 (46.5)	480 (87.9)	66 (12.1)
ARTS-DN	Bakris et al	2015	JAMA	Finerenone	821	182 (22.2)	691 (84.2)	130 (15.8)
AMETHYST- DN	Bakris et al	2015	JAMA	Patiromer dosage	304 <sup>e</sup>	112 (36.8)	304 (100.0)	0 (0.0)
DETAIL	Barnett et al	2004	NEJM	Telmisartan vs Enalapril	250	68 (27.2)	246 (98.4)	4 (1.6)
SCORED	Bhatt et al	2021	NEJM	Sotagliflozin	10584	4754 (44.9)	8749 (82.7)	1835 (17.3)
SOLOIST- WHF	Bhatt et al	2021	NEJM	Sotagliflozin	1222	412 (33.7)	1139 (93.2)	83 (6.8)
AWARD-4	Blonde et al	2015	Lancet	Dulaglutide, Glargine	884	411 (46.5)	697 (78.8)	187 (21.2)
RENAAL	Brenner et al	2001	NEJM	Losartan	1513	557 (36.8)	736 (48.6)	777 (51.4)
DURATION-6	Buse et al	2013	Lancet	Exenatide vs Liraglutide	911	412 (45.2)	753 (82.7)	158 (17.3)
LEAD-6	Buse et al	2009	Lancet	Liraglutide vs Exenatide	464	223 (48.1)	426 (91.8)	38 (8.2)

Davies et al	Davies et al	2017	JAMA	Semaglutide	630	235 (37.3)	523 (83.0)	107 (17.0)
DURATION-3	Diamant et al	2010	Lancet	Exenatide vs Insulin Glargine	456	213 (46.7)	379 (83.1)	77 (16.9)
PROactive	Dormandy et al	2005	Lancet	Pioglitazone	5238	1775 (33.9)	5164 (98.6)	74 (1.4)
DURATION-1	Drucker et al	2008	Lancet	Exenatide	295	138 (46.8)	230 (78.0)	65 (22.0)
VADT	Duckworth et al	2009	NEJM	Intensive vs standard glucose control	1791	52 (2.9)	1111 (62.0)	680 (38.0)
AWARD-6	Dungan et al	2014	Lancet	Dulaglutide vs Liraglutide	599	312 (52.1)	515 (86.0)	84 (14.0)
VA NEPHRON-D	Fried et al	2013	NEJM	Lisinopril	1448	12 (0.8)	1037 (71.6)	411 (28.4)
EUREXA	Gallwitz et al	2012	Lancet	Exenatide vs Glimepiride	977	453 (46.4)	894 (91.5)	83 (8.5)
LEAD-3 Mono	Garber et al	2009	Lancet	Liraglutide vs Glimepiride	746	375 (50.3)	583 (78.2)	163 (21.8)

BEGIN-Basal-Bolus Type 2	Heller et al	2012	Lancet	Insulin degludec vs insulin glargine	629	261 (41.5)	585 (93.0)	44 (7.0)
ROADMAP	Haller et al	2011	NEJM	Olmesartan	4447	2395 (53.9)	4447 (100.0)	0 (0.0)
4-T Study Group	Holman et al	2007	NEJM	Biphasic vs prandial vs basal insulin	708	254 (35.9)	653 (92.2)	55 (7.8)
RECORD	Home et al	2007	NEJM	Rosiglitazone vs metformin plus sulfonylurea	4447	2153 (48.4)	4399 (98.9)	48 (1.1)
ADOPT	Kahn et al	2006	NEJM	Rosiglitazone vs metformin vs glyburide	4351 <sup>f</sup>	1840 (42.3)	3847 (88.4)	504 (11.6)
Lewis et al	Lewis et al	2001	NEJM	Irbesartan, Amlodipine	1715	575 (33.5)	1242 (72.4)	473 (27.6)
SUSTAIN-6	Marso et al	2016	NEJM	Semaglutide	3297	1295 (39.3)	2736 (83.0)	561 (17.0)
VERIFY	Matthews et al	2019	Lancet	Vildagliptin, Metformin	2001	1060 (53.0)	1217 (60.8)	784 (39.2)
IRMA-2	Parving et al	2001	NEJM	Irbesartan	590 <sup>g</sup>	184 (31.2)	574 (97.3)	16 (2.7)
AVOID	Parving et al	2008	NEJM	Aliskiren, losartan	599	172 (28.7)	520 (86.8)	79 (13.2)

TREAT	Pfeffer et al	2009	NEJM	Darbepoetin Alfa	4038	2312 (57.3)	2570 (63.6)	1468 (36.4)
1860-LIRA-DPP-4	Pratley et al	2010	Lancet	Liraglutide vs sitagliptin	665	313 (47.1)	576 (86.6)	89 (13.4)
Rosenstock et al	Rosenstock et al	2010	Lancet	inhaled insulin, glargine vs biaspart	618 <sup>h</sup>	328 (53.1)	417 (67.5)	201 (32.5)
INTERVAL	Strain et al	2013	Lancet	Vildagliptin	278	152 (54.7)	269 (96.8)	9 (3.2)
Zinman et al	Zinman et al	2011	Lancet	Insulin degludec, glargine, Metformin	245	108 (44.1)	78 (31.8)	167 (68.2)
Satoh et al	Satoh et al	2003	Diabetes Care	Pioglitazone	136	72 (52.9)	0 (0.0)	136 (100.0)
Tanamas et al	Tanamas et al	2016	Diabetes Care	Losartan	169	111 (65.7)	0 (0.0)	169 (100.0)
Vellanki et al	Vellanki et al	2015	Diabetes Care	insulin supplementation	206	92 (44.7)	34 (16.5)	172 (83.5)
GRADE	Wexler et al	2019	Diabetes Care	Glimepiride, Sitagliptin,	5047	1837 (36.4)	3314 (65.7)	1733 (34.3)

				liraglutide, insulin glargine, metformin				
UKPDS 57	Wright et al	2002	Diabetes Care	insulin vs diet control	826	339 (41.1)	653 (79.1)	173 (20.9)

717

718

Footnotes:

719

a) 514 participants were randomized but the baseline characteristics are only available for 491 participants who were included in the final analysis.

720

b) 318 participants were randomized but demographic information is only provided for 316.

721

c) 1552 participants were randomized, 1 was untreated, but demographic information about the untreated participant is not listed.

722

d) 2425 participants were randomized but efficacy analyses and baseline characteristics are only available for 2418.

723

e) 306 participants were recruited, but only 304 were included in the analysis.

724

f) 4360 participants were randomized but 9 of these participants did not receive study medication.

725

g) 611 participants were randomized, but 21 participants were excluded.

726

h) 677 participants were randomized but only 618 participants were reported for baseline characteristics.

727

728 **Figures**

729 **Figure 1. Representation of Non-White and White Participants in Industry vs. Government**  
730 **Funded Trials**

731 Figure legend: Bars represent 95% confidence intervals.

732

733 **Figure 2a. Forest plot of comparison: PPR White People – Industry Trials**

734 Figure Legend: Individual PPRs of 68 industry-funded trials are shown along with a pooled PPR  
735 for the white population. Lines represent 95% confidence intervals.

736

737 **Figure 2b. Forest plot of comparison: PPR Non-White People – Industry Trials**

738 Figure Legend: Individual PPRs of 68 industry-funded trials are shown along with a pooled PPR  
739 for the non-white population. Lines represent 95% confidence intervals.

740

741 **Figure 3a. Forest plot of comparison: PPR White People – Government Trials**


742 Figure Legend: Individual PPRs of 14 government-funded trials are shown along with a pooled  
743 PPR for the white population. Lines represent 95% confidence intervals.


744


745 **Figure 3b. Forest plot of comparison: PPR Non-White People – Government Trials**

746 Figure Legend: Individual PPRs of 14 government-funded trials are shown along with a pooled  
747 PPR for the non-white population. Lines represent 95% confidence intervals.

### Representation of Non-White and White Participants in Industry vs Government-funded Trials








Study or Subgroup	log[Participant to Prevalence Ratio]	SE	White Non-White		Weight	Participant to Prevalence Ratio	
			Total	Total		IV, Random, 95% CI	IV, Random, 95% CI
ACCORD 2010	0.284088	0.02063059	6604	3647	10.8%	1.33	[1.28, 1.38]
BARI 2D 2013	0.30706866	0.04335634	1561	807	10.2%	1.36	[1.25, 1.48]
CARDS 2004	0.13977786	0.08091064	2676	162	8.7%	1.15	[0.98, 1.35]
Fayfman et al 2019	-0.5732755	0.18320632	41	109	4.7%	0.56	[0.39, 0.81]
FIELD 2005	0.11145231	0.03917239	9093	702	10.3%	1.12	[1.04, 1.21]
GRADE 2019	0.30314965	0.02964429	3314	1733	10.6%	1.35	[1.28, 1.44]
Satoh et al 2003	-0.7857953	1.41681083	0	136	0.1%	0.46	[0.03, 7.32]
Tanamas et al 2016	-5.10221237	1.41630405	0	169	0.1%	0.01	[0.00, 0.10]
TINSAL-T2D 2010	0.04898969	0.1924831	55	53	4.5%	1.05	[0.72, 1.53]
TINSAL-T2D-II 2013	0.08507576	0.11844798	151	135	7.1%	1.09	[0.86, 1.37]
UKPDS 57 2002	-0.03646335	0.08550871	653	173	8.5%	0.96	[0.82, 1.14]
VADT 2009	0.24627412	0.04868961	1111	680	10.0%	1.28	[1.16, 1.41]
VA NEPHRON-D 2013	0.38993637	0.05828731	1037	411	9.7%	1.48	[1.32, 1.66]
Vellanki et al 2015	-1.07772791	0.18768516	34	172	4.6%	0.34	[0.24, 0.49]
<b>Total (95% CI)</b>			<b>26330</b>	<b>9089</b>	<b>100.0%</b>	<b>1.11</b>	<b>[1.00, 1.23]</b>

Heterogeneity: Tau<sup>2</sup> = 0.03; Chi<sup>2</sup> = 127.06, df = 13 (P < 0.00001); I<sup>2</sup> = 90%  
 Test for overall effect: Z = 1.91 (P = 0.06)



Study or Subgroup	log[Participant to Prevalence Ratio]	SE	Non-White		White		Weight	Participant to Prevalence Ratio	
			Total	Total	Total	Total		IV, Random, 95% CI	Participant to Prevalence Ratio IV, Random, 95% CI
ACCORD 2010	-0.37005273	0.02063059	3647	6604	9.4%		0.69	[0.66, 0.72]	
BARI 2D 2013	-0.4130597	0.04335634	807	1561	9.2%		0.66	[0.61, 0.72]	
CARDS 2004	-1.1489308	0.08091064	162	2676	8.7%		0.32	[0.27, 0.37]	
Fayfman et al 2019	0.34413021	0.18320632	109	41	6.4%		1.41	[0.99, 2.02]	
FIELD 2005	-0.8612428	0.03917239	702	9093	9.3%		0.42	[0.39, 0.46]	
GRADE 2019	-0.40552237	0.02964429	1733	3314	9.4%		0.67	[0.63, 0.71]	
Satoh et al 2003	0.00439993	1.41681083	136	0	0.3%		1.00	[0.06, 16.14]	
Tanamas et al 2016	0.66046341	1.41630405	169	0	0.3%		1.94	[0.12, 31.07]	
TINSAL-T2D 2010	-0.04842169	0.1924831	53	55	6.2%		0.95	[0.65, 1.39]	
TINSAL-T2D-II 2013	-0.0872994	0.11844798	135	151	7.9%		0.92	[0.73, 1.16]	
UKPDS 57 2002	0.15102455	0.08550871	173	653	8.6%		1.16	[0.98, 1.38]	
VADT 2009	-0.30501898	0.04868961	680	1111	9.2%		0.74	[0.67, 0.81]	
VA NEPHRON-D 2013	-0.59592773	0.05828731	411	1037	9.0%		0.55	[0.49, 0.62]	
Vellanki et al 2015	0.48303593	0.18768516	172	34	6.3%		1.62	[1.12, 2.34]	
<b>Total (95% CI)</b>			<b>9089</b>	<b>26330</b>	<b>100.0%</b>		<b>0.73</b>	<b>[0.62, 0.86]</b>	

Heterogeneity: Tau<sup>2</sup> = 0.07; Chi<sup>2</sup> = 324.44, df = 13 (P < 0.00001); I<sup>2</sup> = 96%  
Test for overall effect: Z = 3.88 (P = 0.0001)

